Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells

Chimeric antigen receptor (CAR)-T therapy requires autologous T lymphocytes from cancer patients, a process that is both costly and complex. Universal CAR-T cell treatment from allogeneic sources can overcome this limitation but is impeded by graft-versus-host disease (GvHD) and host versus-graft rejection (HvGR). Here, we introduce a mutated calcineurin subunit A (CNA) and a CD19-specific CAR into the T cell receptor α constant (TRAC) locus to generate cells that are resistant to the widely used immunosuppressant, cyclosporine A (CsA). These immunosuppressant-resistant universal (IRU) CAR-T cells display improved effector function in vitro and anti-tumour efficacy in a leukemia xenograft mouse model in the presence of CsA, compared with CAR-T cells carrying wild-type CNA. Moreover, IRU CAR-T cells retain effector function in vitro and in vivo in the presence of both allogeneic T cells and CsA. Lastly, CsA withdrawal restores HvGR, acting as a safety switch that can eliminate IRU CAR-T cells. These findings demonstrate the efficacy of CsA-resistant CAR-T cells as a universal, ‘off-the-shelf’ treatment option.


Statistics
For all statistical analyses, confirm that the following items are present in in the figure legend, table legend, main text, or or Methods section.

n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as as a discrete number and unit of of measurement A statement on on whether measurements were taken from distinct samples or or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.

A description of of all covariates tested
A description of of any assumptions or or corrections, such as as tests of of normality and adjustment for multiple comparisons A full description of of the statistical parameters including central tendency (e.g.means) or or other basic estimates (e.g.regression coefficient) AND variation (e.g. standard deviation) or or associated estimates of of uncertainty (e.g.confidence intervals) For null hypothesis testing, the test statistic (e.g.F, t, r) with confidence intervals, effect sizes, degrees of of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on on the choice of of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of of the appropriate level for tests and full reporting of of outcomes Estimates of of effect sizes (e.g.Cohen's d, Pearson's r), ), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Data analysis
For manuscripts utilizing custom algorithms or or software that are central to to the research but not yet described in in published literature, software must be be made available to to editors and reviewers.We We strongly encourage code deposition in in a community repository (e.g.GitHub).See the Nature Portfolio guidelines for submitting code & software for further information.

Data Policy information about availability of of data
All manuscripts must include a data availability statement This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or or web links for publicly available datasets -A description of of any restrictions on on data availability -For clinical datasets or or third party data, please ensure that the statement adheres to to our policy The RNA-seq data has been deposited in in the Sequence Read Archive (SRA) under accession code PRJNA880631 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA880631).The raw data generated in in this study is is provided in in the Source Data file.

nature portfolio | reporting summary
March 2021

Human research participants
Policy information about studies involving human research participants and Sex and Gender in Research.

Recruitment
Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting
Please select the one below that is the best fit for your research.If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study
All studies must disclose on these points even when the disclosure is negative.No statistical methods were used to pre-determine sample size.Sample sizes were estimated based on preliminary experiments, with an effort to achieve a minimum of n=5 mice per treatment group unless specified.
No data were excluded throughout the studies.
All experiments were repeated with similar results as shown in figures and stated in the figure legends.
No mice were excluded.Mice were randomly assigned into control or treatment groups by an operator who was blinded to the experiments.
Mouse condition and survival were observed by an operator who was blinded to treatment groups in addition to the main investigator who was not blind to group allocation.Tumor burden and other data analyses are based on objectively measurable data (e.g.fluorescence intensity).As the outcomes of survival and tumor burden were objective, the involvement of one investigator who was not blind to group allocation would not influence the interpretation of outcome.
We require information from authors about some types of materials, experimental systems and methods used in many studies.Here, indicate whether each material, system or method listed is relevant to your study.If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.Volunteers are Asian people in the age range of 25-46, female and male.Healthy participants were recruited through public recruitment advertisement which was approved by the First Affiliated Hospital, College of Medicine, Zhejiang University.Fresh PBMCs from healthy donors were provided by the First Affiliated Hospital, College of Medicine, Zhejiang University.The recruitments of healthy human blood donors were approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University.All the participants signed the Informed Consent Form.All experiments conducted on human material were approved by the Clinical Research Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine in 2022, No. 1013-Quick.